-
Product Insights
Aneurysm – Drugs In Development, 2023
Global Markets Direct’s, ‘Aneurysm - Drugs In Development, 2023’, provides an overview of the Aneurysm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Aneurysm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levosimendan in Diastolic Heart Failure (HFpEF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levosimendan in Diastolic Heart Failure (HFpEF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levosimendan in Diastolic Heart Failure (HFpEF) Drug Details: Levosimendan (Simdax,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levosimendan in Pulmonary Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levosimendan in Pulmonary Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levosimendan in Pulmonary Hypertension Drug Details: Levosimendan (Simdax, Zimino) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tin-117M-Dota-Annexin V in Abdominal Aortic Aneurysm
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Tin-117M-Dota-Annexin V in Abdominal Aortic AneurysmDrug Details:Tin-117m-DOTA-Annexin V is under development for the treatment of carotid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satralizumab in Graves’ Ophthalmopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Graves' Ophthalmopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Satralizumab in Graves' Ophthalmopathy Drug Details: Satralizumab (Enspryng) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satralizumab in Myasthenia Gravis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Myasthenia Gravis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Satralizumab in Myasthenia Gravis Drug Details: Satralizumab (Enspryng) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satralizumab in Demyelinating Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Demyelinating Diseases report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Satralizumab in Demyelinating Diseases Drug Details: Satralizumab (Enspryng) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Pulmonary Sarcoidosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Pulmonary Sarcoidosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pulmonary Sarcoidosis Drug Details: Canakinumab (Ilaris / Lasprona /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Canakinumab in Pyoderma Gangrenosum
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Canakinumab in Pyoderma Gangrenosum report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Canakinumab in Pyoderma Gangrenosum Drug Details: Canakinumab (Ilaris / Lasprona /...